XI. Literaturverzeichnis

1. Jungck, M., W. Friedl, and P. Propping, *[Hereditary gastrointestinal tumors]*. Internist (Berl), 1999. **40**(5): p. 502-12.
2. Boyle, P. and J.S. Langman, *ABC of colorectal cancer: Epidemiology.* Bmj, 2000. **321**(7264): p. 805-8.
3. Lordick, F., et al., *[Adjuvant therapy for colon cancer]*. Dtsch Med Wochenschr, 2004. **129**(44): p. 2366-71.
4. Beart, R.W., et al., *Trends in right and left-sided colon cancer.* Dis Colon Rectum, 1983. **26**(6): p. 393-8.
5. Slater, G.I., R.H. Haber, and A.H. Aufses, Jr., *Changing distribution of carcinoma of the colon and rectum.* Surg Gynecol Obstet, 1984. **158**(3): p. 216-8.
6. Sobin, L.H., P. Hermanek, and R.V. Hutter, *TNM classification of malignant tumors. A comparison between the new (1987) and the old editions.* Cancer, 1988. **61**(11): p. 2310-4.
7. Hermanek, P., C. Wittekind, and H.J. Seib, *[Current TNM aspects. 5. TNM classification and stage grouping]*. Zentralbl Chir, 1997. **122**(10): p. 934-7.
8. Berger, D.P., E. R., and M. R., *Das rote Buch, Hämatologie und internistische Onkologie, 2. Auflage.* ecomed Verlagsgesellschaft mbH & Co.KG., 2002. p. 594 and 597.
9. Compton, C., et al., *American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.* Cancer, 2000. **88**(7): p. 1739-57.
10. Müller, M. and Mitarbeiter, *Chirurgie für Studium und Praxis, 7. Auflage.* Medizinische Verlags- und Informationsdienste, Breisach am Rhein, 2004/05: p. 182-187.
11. Burt, R. and D.W. Neklason, *Genetic testing for inherited colon cancer.* Gastroenterology, 2005. **128**(6): p. 1696-716.
12. Hampton, G., et al., *Characterization and mapping of microdissected genomic clones from the adenomatous polyposis coli (APC) region.* Genomics, 1991. **11**(2): p. 247-51.
13. Kinzler, K.W., et al., *Identification of FAP locus genes from chromosome 5q21.* Science, 1991. **253**(5020): p. 661-5.
14. Thomas, G., *Advances in the genetics and molecular biology of colorectal tumors.* Curr Opin Oncol, 1994. **6**(4): p. 406-12.
15. Boland, C.R., *Roles of the DNA mismatch repair genes in colorectal tumorigenesis.* Int J Cancer, 1996. **69**(1): p. 47-9.
16. al-Taie, O., et al., *[Hereditary nonpolyposis colorectal carcinoma (HNPCC). Current review of etiology, clinical aspects, diagnosis and therapy]*. Med Klin (Munich), 2001. **96**(9): p. 529-38.
17. Ahnen, D.J., *Lessons from the genetics of colon cancer.* Scand J Gastroenterol Suppl, 1990. **175**: p. 166-76.
18. Burt, R.W., et al., *Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer.* Bull World Health Organ, 1990. **68**(5): p. 655-65.
19. Jenne, D.E., et al., *Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.* Nat Genet, 1998. **18**(1): p. 38-43.
20. Olschwang, S., et al., *Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3.* J Med Genet, 1998. **35**(1): p. 42-4.
21. Howe, J.R., et al., *Mutations in the SMAD4/DPC4 gene in juvenile polyposis.* Science, 1998. **280**(5366): p. 1086-8.
22. Woodford-Richens, K., et al., *Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium.* Cancer Res, 2000. **60**(9): p. 2477-82.

23. Frayling, I.M., W.F. Bodmer, and I.P. Tomlinson, *Allele loss in colorectal cancer at the Cowden disease/juvenile polyposis locus on 10q.* Cancer Genet Cytogenet, 1997. **97**(1): p. 64-9.
24. Zhou, X.P., et al., *PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.* Am J Pathol, 2002. **161**(2): p. 439-47.
25. Midgley, R. and D. Kerr, *Colorectal cancer.* Lancet, 1999. **353**(9150): p. 391-9.
26. Nicum, S., R. Midgley, and D.J. Kerr, *Colorectal cancer.* Acta Oncol, 2003. **42**(4): p. 263-75.
27. Tanyi, M., et al., *[Clinical significance of HNPCC, surgical aspects of early recognition].* Magy Seb, 2004. **57**(5): p. 267-78.
28. Bellacosa, A., et al., *Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects.* Am J Med Genet, 1996. **62**(4): p. 353-64.
29. Abdel-Rahman, W.M., J.P. Mecklin, and P. Peltomaki, *The genetics of HNPCC: Application to diagnosis and screening.* Crit Rev Oncol Hematol, 2006.
30. Peltomaki, P. and H. Vasen, *Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database.* Dis Markers, 2004. **20**(4-5): p. 269-76.
31. Peltomaki, P. and A. de la Chapelle, *Mutations predisposing to hereditary nonpolyposis colorectal cancer.* Adv Cancer Res, 1997. **71**: p. 93-119.
32. Amos, C.I., et al., *Fine mapping of a genetic locus for Peutz-Jeghers syndrome on chromosome 19p.* Cancer Res, 1997. **57**(17): p. 3653-6.
33. Hemminki, A., et al., *A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.* Nature, 1998. **391**(6663): p. 184-7.
34. Gruber, S.B., et al., *Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome.* Cancer Res, 1998. **58**(23): p. 5267-70.
35. Miller, A.B., *Diet and cancer. A review.* Acta Oncol, 1990. **29**(1): p. 87-95.
36. Peters, U., et al., *Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme.* Lancet, 2003. **361**(9368): p. 1491-5.
37. Bingham, S.A., et al., *Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study.* Lancet, 2003. **361**(9368): p. 1496-501.
38. Harris, D.M. and V.L. Go, *Vitamin D and colon carcinogenesis.* J Nutr, 2004. **134**(12 Suppl): p. 3463S-3471S.
39. Sheldon, C.A., et al., *Carcinoma at the site of ureterosigmoidostomy.* Dis Colon Rectum, 1983. **26**(1): p. 55-8.
40. Adami, H.O., et al., *Colorectal cancer after cholecystectomy: absence of risk increase within 11-14 years.* Gastroenterology, 1983. **85**(4): p. 859-65.
41. Fearon, E.R. and B. Vogelstein, *A genetic model for colorectal tumorigenesis.* Cell, 1990. **61**(5): p. 759-67.
42. Vogelstein, B. and K.W. Kinzler, *The multistep nature of cancer.* Trends Genet, 1993. **9**(4): p. 138-41.
43. Giles, R.H., J.H. van Es, and H. Clevers, *Caught up in a Wnt storm: Wnt signaling in cancer.* Biochim Biophys Acta, 2003. **1653**(1): p. 1-24.
44. Lustig, B. and J. Behrens, *The Wnt signaling pathway and its role in tumor development.* J Cancer Res Clin Oncol, 2003. **129**(4): p. 199-221.
45. Kinzler, K.W. and B. Vogelstein, *Lessons from hereditary colorectal cancer.* Cell, 1996. **87**(2): p. 159-70.
46. Heinimann, K., et al., *Phenotypic differences in familial adenomatous polyposis based on APC gene mutation status.* Gut, 1998. **43**(5): p. 675-9.

47. Muller, O., et al., *A beta-catenin mutation in a sporadic colorectal tumor of the RER phenotype and absence of beta-catenin germline mutations in FAP patients.* Genes Chromosomes Cancer, 1998. **22**(1): p. 37-41.
48. Fearon, E.R., et al., *Identification of a chromosome 18q gene that is altered in colorectal cancers.* Science, 1990. **247**(4938): p. 49-56.
49. Hahn, S.A., et al., *DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.* Science, 1996. **271**(5247): p. 350-3.
50. *Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und ihrer Arbeitsgemeinschaft, der Deutschen Gesellschaft für Chirurgie und der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Kolonkarzinom.* 1999.
51. Liu, L.X., W.H. Zhang, and H.C. Jiang, *Current treatment for liver metastases from colorectal cancer.* World J Gastroenterol, 2003. **9**(2): p. 193-200.
52. *Allgemeine und spezielle Pharmakologie, 8. Auflage.* Urban & Fischer, München und Jena., 2001: p. 964-65.
53. *Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.* J Clin Oncol, 1992. **10**(6): p. 896-903.
54. Lorenz, M., et al., *Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.* Ann Oncol, 2001. **12**(3): p. 321-5.
55. Carmichael, J., et al., *Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.* J Clin Oncol, 2002. **20**(17): p. 3617-27.
56. Van Cutsem, E., et al., *Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.* Br J Cancer, 2004. **90**(6): p. 1190-7.
57. Cunningham, D., et al., *Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.* Eur J Cancer, 2002. **38**(4): p. 478-86.
58. Cunningham, D., et al., *'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.* Eur J Cancer, 1995. **31A**(12): p. 1945-54.
59. Cocconi, G., et al., *Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.* J Clin Oncol, 1998. **16**(9): p. 2943-52.
60. Machover, D., et al., *Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.* Ann Oncol, 1996. **7**(1): p. 95-8.
61. Raymond, E., et al., *Oxaliplatin: a review of preclinical and clinical studies.* Ann Oncol, 1998. **9**(10): p. 1053-71.
62. Cvitkovic, E. and M. Bekradda, *Oxaliplatin: a new therapeutic option in colorectal cancer.* Semin Oncol, 1999. **26**(6): p. 647-62.
63. Creemers, G.J., et al., *Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.* Ann Oncol, 1995. **6**(8): p. 844-6.
64. Cunningham, D., et al., *Optimizing the use of irinotecan in colorectal cancer.* Oncologist, 2001. **6 Suppl 4**: p. 17-23.
65. Hickman, J.A., *Apoptosis induced by anticancer drugs.* Cancer Metastasis Rev, 1992. **11**(2): p. 121-39.
66. Fisher, D.E., *Apoptosis in cancer therapy: crossing the threshold.* Cell, 1994. **78**(4): p. 539-42.

67. Makin, G. and C. Dive, *Apoptosis and cancer chemotherapy.* Trends Cell Biol, 2001. **11**(11): p. S22-6.
68. Johnstone, R.W., A.A. Ruefli, and S.W. Lowe, *Apoptosis: a link between cancer genetics and chemotherapy.* Cell, 2002. **108**(2): p. 153-64.
69. Jimenez, G.S., et al., *p53 regulation by post-translational modification and nuclear retention in response to diverse stresses.* Oncogene, 1999. **18**(53): p. 7656-65.
70. Soussi, T., *The p53 tumor suppressor gene: from molecular biology to clinical investigation.* Ann N Y Acad Sci, 2000. **910**: p. 121-37; discussion 137-9.
71. Carr, A.M., *Cell cycle. Piecing together the p53 puzzle.* Science, 2000. **287**(5459): p. 1765-6.
72. Giaccia, A.J. and M.B. Kastan, *The complexity of p53 modulation: emerging patterns from divergent signals.* Genes Dev, 1998. **12**(19): p. 2973-83.
73. Ashcroft, M., M.H. Kubbutat, and K.H. Vousden, *Regulation of p53 function and stability by phosphorylation.* Mol Cell Biol, 1999. **19**(3): p. 1751-8.
74. Appella, E. and C.W. Anderson, *Signaling to p53: breaking the posttranslational modification code.* Pathol Biol (Paris), 2000. **48**(3): p. 227-45.
75. Bates, S. and K.H. Vousden, *Mechanisms of p53-mediated apoptosis.* Cell Mol Life Sci, 1999. **55**(1): p. 28-37.
76. Sionov, R.V. and Y. Haupt, *The cellular response to p53: the decision between life and death.* Oncogene, 1999. **18**(45): p. 6145-57.
77. Abraham, R.T., *Cell cycle checkpoint signaling through the ATM and ATR kinases.* Genes Dev, 2001. **15**(17): p. 2177-96.
78. Agarwal, M.L., et al., *A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides.* Proc Natl Acad Sci U S A, 1998. **95**(25): p. 14775-80.
79. Meek, D.W., *The role of p53 in the response to mitotic spindle damage.* Pathol Biol (Paris), 2000. **48**(3): p. 246-54.
80. Kastan, M.B., et al., *A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.* Cell, 1992. **71**(4): p. 587-97.
81. Bunz, F., et al., *Requirement for p53 and p21 to sustain G2 arrest after DNA damage.* Science, 1998. **282**(5393): p. 1497-501.
82. Elledge, S.J., *Cell cycle checkpoints: preventing an identity crisis.* Science, 1996. **274**(5293): p. 1664-72.
83. Di Leonardo, A., et al., *DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.* Genes Dev, 1994. **8**(21): p. 2540-51.
84. *Molekulare Genetik.* Thieme Verlag, 2000.
85. Agami, R. and R. Bernards, *Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle.* Cancer Lett, 2002. **177**(2): p. 111-8.
86. Brehm, A., et al., *Retinoblastoma protein recruits histone deacetylase to repress transcription.* Nature, 1998. **391**(6667): p. 597-601.
87. Deng, C., et al., *Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.* Cell, 1995. **82**(4): p. 675-84.
88. Landes Bioscience, 2000-2005.
89. O'Connell, M.J., N.C. Walworth, and A.M. Carr, *The G2-phase DNA-damage checkpoint.* Trends Cell Biol, 2000. **10**(7): p. 296-303.
90. Draetta, G., et al., *Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolytic inactivation of MPF.* Cell, 1989. **56**(5): p. 829-38.
91. Morgan, D.O., *Principles of CDK regulation.* Nature, 1995. **374**(6518): p. 131-4.

92. Kumagai, A. and W.G. Dunphy, *The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system.* Cell, 1991. **64**(5): p. 903-14.
93. Lee, M.S., et al., *cdc25+ encodes a protein phosphatase that dephosphorylates p34cdc2.* Mol Biol Cell, 1992. **3**(1): p. 73-84.
94. Matsuoka, S., M. Huang, and S.J. Elledge, *Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.* Science, 1998. **282**(5395): p. 1893-7.
95. Brown, A.L., et al., *A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage.* Proc Natl Acad Sci U S A, 1999. **96**(7): p. 3745-50.
96. Liu, Q., et al., *Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.* Genes Dev, 2000. **14**(12): p. 1448-59.
97. Zeng, Y., et al., *Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1.* Nature, 1998. **395**(6701): p. 507-10.
98. Furnari, B., et al., *Cdc25 inhibited in vivo and in vitro by checkpoint kinases Cds1 and Chk1.* Mol Biol Cell, 1999. **10**(4): p. 833-45.
99. Peng, C.Y., et al., *Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.* Science, 1997. **277**(5331): p. 1501-5.
100. Zeng, Y. and H. Piwnica-Worms, *DNA damage and replication checkpoints in fission yeast require nuclear exclusion of the Cdc25 phosphatase via 14-3-3 binding.* Mol Cell Biol, 1999. **19**(11): p. 7410-9.
101. Taylor, W.R. and G.R. Stark, *Regulation of the G2/M transition by p53.* Oncogene, 2001. **20**(15): p. 1803-15.
102. Stucke, V.M., *Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication.* Dissertation, 2003: p. 19-22.
103. Michaelis, C., R. Ciosk, and K. Nasmyth, *Cohesins: chromosomal proteins that prevent premature separation of sister chromatids.* Cell, 1997. **91**(1): p. 35-45.
104. Waizenegger, I.C., et al., *Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase.* Cell, 2000. **103**(3): p. 399-410.
105. Uhlmann, F., et al., *Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast.* Cell, 2000. **103**(3): p. 375-86.
106. Yin, X.Y., et al., *C-myc overexpression and p53 loss cooperate to promote genomic instability.* Oncogene, 1999. **18**(5): p. 1177-84.
107. Tarapore, P. and K. Fukasawa, *p53 mutation and mitotic infidelity.* Cancer Invest, 2000. **18**(2): p. 148-55.
108. Sablina, A.A., et al., *p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system.* Cell Biol Int, 1999. **23**(5): p. 323-34.
109. Daniel, P.T., *Zellzyklus und Apoptose. In: Molekularmedizinische Grundlagen von hämatologischen Neoplasien.* Ganten, Ruckpaul. Heidelberg: Springer-Verlag, 2003a: p. 130-74.
110. Harley, C.B., A.B. Futcher, and C.W. Greider, *Telomeres shorten during ageing of human fibroblasts.* Nature, 1990. **345**(6274): p. 458-60.
111. Karlseder, J., A. Smogorzewska, and T. de Lange, *Senescence induced by altered telomere state, not telomere loss.* Science, 2002. **295**(5564): p. 2446-9.
112. Roninson, I.B., *Tumor cell senescence in cancer treatment.* Cancer Res, 2003. **63**(11): p. 2705-15.
113. Pearson, M., et al., *PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.* Nature, 2000. **406**(6792): p. 207-10.

114. Ferbeyre, G., et al., *PML is induced by oncogenic ras and promotes premature senescence.* Genes Dev, 2000. **14**(16): p. 2015-27.
115. Noda, A., et al., *Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen.* Exp Cell Res, 1994. **211**(1): p. 90-8.
116. Alcorta, D.A., et al., *Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.* Proc Natl Acad Sci U S A, 1996. **93**(24): p. 13742-7.
117. Stein, G.H., et al., *Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.* Mol Cell Biol, 1999. **19**(3): p. 2109-17.
118. Serrano, M., et al., *Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.* Cell, 1997. **88**(5): p. 593-602.
119. Weinberg, R.A., *The cat and mouse games that genes, viruses, and cells play.* Cell, 1997. **88**(5): p. 573-5.
120. Chang, B.D., et al., *A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.* Cancer Res, 1999. **59**(15): p. 3761-7.
121. Lundberg, A.S., et al., *Genes involved in senescence and immortalization.* Curr Opin Cell Biol, 2000. **12**(6): p. 705-9.
122. Campisi, J., *Cellular senescence as a tumor-suppressor mechanism.* Trends Cell Biol, 2001. **11**(11): p. S27-31.
123. Shelton, D.N., et al., *Microarray analysis of replicative senescence.* Curr Biol, 1999. **9**(17): p. 939-45.
124. Dimri, G.P., et al., *A biomarker that identifies senescent human cells in culture and in aging skin in vivo.* Proc Natl Acad Sci U S A, 1995. **92**(20): p. 9363-7.
125. Mathon, N.F. and A.C. Lloyd, *Cell senescence and cancer.* Nat Rev Cancer, 2001. **1**(3): p. 203-13.
126. Sherr, C.J. and R.A. DePinho, *Cellular senescence: mitotic clock or culture shock?* Cell, 2000. **102**(4): p. 407-10.
127. Harvey, M., et al., *In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice.* Oncogene, 1993. **8**(9): p. 2457-67.
128. Dimri, G.P., et al., *Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor.* Mol Cell Biol, 2000. **20**(1): p. 273-85.
129. Malumbres, M., et al., *Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b).* Mol Cell Biol, 2000. **20**(8): p. 2915-25.
130. Sage, J., et al., *Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.* Genes Dev, 2000. **14**(23): p. 3037-50.
131. Russell, P. and P. Nurse, *cdc25+ functions as an inducer in the mitotic control of fission yeast.* Cell, 1986. **45**(1): p. 145-53.
132. Kimura, K., et al., *Phosphorylation and activation of 13S condensin by Cdc2 in vitro.* Science, 1998. **282**(5388): p. 487-90.
133. Karsenti, E. and I. Vernos, *The mitotic spindle: a self-made machine.* Science, 2001. **294**(5542): p. 543-7.
134. Gonczy, P., *Nuclear envelope: torn apart at mitosis.* Curr Biol, 2002. **12**(7): p. R242-4.
135. Castedo, M., et al., *Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy.* Oncogene, 2004. **23**(25): p. 4362-70.
136. Chan, T.A., et al., *14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage.* Nature, 1999. **401**(6753): p. 616-20.

137. Lock, R.B. and L. Stribinskiene, *Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival.* Cancer Res, 1996. **56**(17): p. 4006-12.
138. Nabha, S.M., et al., *Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.* Clin Cancer Res, 2002. **8**(8): p. 2735-41.
139. Cogswell, J.P., et al., *Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.* Cell Growth Differ, 2000. **11**(12): p. 615-23.
140. Fu, M., et al., *Minireview: Cyclin D1: normal and abnormal functions.* Endocrinology, 2004. **145**(12): p. 5439-47.
141. Sherr, C.J., *Cancer cell cycles.* Science, 1996. **274**(5293): p. 1672-7.
142. Albanese, C., et al., *Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.* J Biol Chem, 1995. **270**(40): p. 23589-97.
143. Shtutman, M., et al., *The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.* Proc Natl Acad Sci U S A, 1999. **96**(10): p. 5522-7.
144. Lin, S.Y., et al., *Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.* Proc Natl Acad Sci U S A, 2000. **97**(8): p. 4262-6.
145. Hulit, J., et al., *Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice.* Mol Cell Biol, 2004. **24**(17): p. 7598-611.
146. Mills, G.B., et al., *Expression of TTK, a novel human protein kinase, is associated with cell proliferation.* J Biol Chem, 1992. **267**(22): p. 16000-6.
147. Hogg, D., et al., *Cell cycle dependent regulation of the protein kinase TTK.* Oncogene, 1994. **9**(1): p. 89-96.
148. Poch, O., et al., *RPK1, an essential yeast protein kinase involved in the regulation of the onset of mitosis, shows homology to mammalian dual-specificity kinases.* Mol Gen Genet, 1994. **243**(6): p. 641-53.
149. Lauze, E., et al., *Yeast spindle pole body duplication gene MPS1 encodes an essential dual specificity protein kinase.* Embo J, 1995. **14**(8): p. 1655-63.
150. Liu, S.T., et al., *Human MPS1 kinase is required for mitotic arrest induced by the loss of CENP-E from kinetochores.* Mol Biol Cell, 2003. **14**(4): p. 1638-51.
151. Stucke, V.M., et al., *Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication.* Embo J, 2002. **21**(7): p. 1723-32.
152. Abrieu, A., et al., *Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint.* Cell, 2001. **106**(1): p. 83-93.
153. Fisk, H.A., C.P. Mattison, and M. Winey, *Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression.* Proc Natl Acad Sci U S A, 2003. **100**(25): p. 14875-80.
154. Stucke, V.M., C. Baumann, and E.A. Nigg, *Kinetochore localization and microtubule interaction of the human spindle checkpoint kinase Mps1.* Chromosoma, 2004. **113**(1): p. 1-15.
155. Magrini, R., et al., *Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.* Int J Cancer, 2002. **101**(1): p. 23-31.
156. Bhonde, M.R., et al., *The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.* Oncogene, 2005. **24**(1): p. 148-56.
157. Bhonde, M.R., et al., *DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53mut cells contributes to apoptosis.* J Biol Chem, 2006.

158. Castedo, M., et al., *Cell death by mitotic catastrophe: a molecular definition.* Oncogene, 2004. **23**(16): p. 2825-37.
159. Chen, X., J. Bargonetti, and C. Prives, *p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis.* Cancer Res, 1995. **55**(19): p. 4257-63.
160. Buettner, R., L.B. Mora, and R. Jove, *Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.* Clin Cancer Res, 2002. **8**(4): p. 945-54.
161. Sinibaldi, D., et al., *Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.* Oncogene, 2000. **19**(48): p. 5419-27.
162. Quintanilla-Martinez, L., et al., *Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.* Am J Pathol, 2003. **162**(5): p. 1449-61.
163. Ma, X.T., et al., *[Relationship of Stat3 and its target gene products with malignancy in human colorectal carcinoma].* Ai Zheng, 2003. **22**(11): p. 1135-9.
164. Lin, Q., et al., *Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.* Am J Pathol, 2005. **167**(4): p. 969-80.
165. Fisk, H.A. and M. Winey, *The mouse Mps1p-like kinase regulates centrosome duplication.* Cell, 2001. **106**(1): p. 95-104.
166. te Poele, R.H. and S.P. Joel, *Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.* Br J Cancer, 1999. **81**(8): p. 1285-93.
167. Wang, Y., et al., *p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.* Oncogene, 2004. **23**(6): p. 1283-90.
168. Hattangadi, D.K., et al., *Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell.* Biochem Pharmacol, 2004. **68**(9): p. 1699-708.
169. Andreassen, P.R., et al., *Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1.* Mol Biol Cell, 2001. **12**(5): p. 1315-28.
170. Andreassen, P.R., et al., *Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells.* Cancer Res, 2001. **61**(20): p. 7660-8.
171. Lanni, J.S. and T. Jacks, *Characterization of the p53-dependent postmitotic checkpoint following spindle disruption.* Mol Cell Biol, 1998. **18**(2): p. 1055-64.
172. Notterman, D., et al., *Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity.* Oncogene, 1998. **17**(21): p. 2743-51.
173. Vogel, C., et al., *Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy.* Oncogene, 2004. **23**(41): p. 6845-53.
174. Borel, F., et al., *Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells.* Proc Natl Acad Sci U S A, 2002. **99**(15): p. 9819-24.
175. Chang, B.D., et al., *p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells.* Oncogene, 2000. **19**(17): p. 2165-70.
176. Castedo, M., et al., *The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.* Oncogene, 2004. **23**(25): p. 4353-61.

177. Michel, L., et al., *Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells.* Proc Natl Acad Sci U S A, 2004. **101**(13): p. 4459-64.
178. Burns, T.F., et al., *Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.* Mol Cell Biol, 2003. **23**(16): p. 5556-71.
179. Tu, S.P., et al., *Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer.* Cancer Res, 2003. **63**(22): p. 7724-32.
180. Stewart, Z.A., M.D. Westfall, and J.A. Pietenpol, *Cell-cycle dysregulation and anticancer therapy.* Trends Pharmacol Sci, 2003. **24**(3): p. 139-45.
181. Martin-Lluesma, S., V.M. Stucke, and E.A. Nigg, *Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2.* Science, 2002. **297**(5590): p. 2267-70.
182. Chen, J.G., et al., *Gene expression and mitotic exit induced by microtubule-stabilizing drugs.* Cancer Res, 2003. **63**(22): p. 7891-9.
183. Shin, H.J., et al., *Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability.* Cancer Cell, 2003. **4**(6): p. 483-97.
184. Roninson, I.B., E.V. Broude, and B.D. Chang, *If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells.* Drug Resist Updat, 2001. **4**(5): p. 303-13.
185. Ivanov, A., et al., *Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks.* J Cell Sci, 2003. **116**(Pt 20): p. 4095-106.
186. Lohr, K., et al., *p21/CDKN1A mediates negative regulation of transcription by p53.* J Biol Chem, 2003. **278**(35): p. 32507-16.
187. Vigneron, A., et al., *The cell cycle inhibitor p21waf1 binds to the Myc and cdc25A promoters upon DNA damage and induces transcriptional repression.* J Biol Chem, 2006.
188. Spurgers, K.B., et al., *Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression.* J Biol Chem, 2006. **281**(35): p. 25134-42.
189. Nitta, M., et al., *Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents.* Oncogene, 2004. **23**(39): p. 6548-58.
190. Miknyoczki, S.J., et al., *Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.* Mol Cancer Ther, 2003. **2**(4): p. 371-82.
191. Monks, A., et al., *UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.* Invest New Drugs, 2000. **18**(2): p. 95-107.
192. Motwani, M., et al., *Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.* Clin Cancer Res, 2001. **7**(12): p. 4209-19.
193. Koizumi, F., et al., *Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.* Int J Cancer, 2004. **108**(3): p. 464-72.
194. Prewett, M.C., et al., *Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.* Clin Cancer Res, 2002. **8**(5): p. 994-1003.
195. Margottin-Goguet, F., et al., *Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase.* Dev Cell, 2003. **4**(6): p. 813-26.